You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
績後獲瑞信唱好石藥(01093.HK)續漲8%獲哮喘靶向治療藥內地授權
阿思達克 08-20 10:02

中期業績多賺25%兼獲瑞信上調評級至「跑贏大市」的石藥集團(01093.HK)今早股價受追捧,公司附屬亦與興盟生物開展合作哮喘藥,該股今早升破百天線(13.48元),最高見14.16元,逼近牛熊線(14.52元),現造13.98元,續漲7.9%為最強藍籌,成交已達3,247萬股,涉資4.47億元。

石藥公布,全資附屬石藥百克與興盟生物醫藥訂立協議,獲對方授出已於03年獲准在美國上市的全球首隻哮喘靶向治療藥物--奧馬珠單抗生物類似藥(SYN008)內地獨家權利,以便其在內地進行該產品有關的所有適應症開發與商業化,該產品已於澳洲完成生物等效研究,並預期短期內在中國申請開展III期臨床試驗。而相關代價則為石藥百克同意向興盟支付1,000萬人民幣首付款及根據該產品於該地區開發進度支付最多5,000萬人民幣之開發里程碑付款,並會根據該產品於該地區達成之銷售額向興盟支付銷售提成。

石藥昨午公布,上半年純利按年升25%至18.78億元人民幣(下同),每股盈利30.13分,維持不派中期息。期內,總收入按年增近28%至111.78億元;毛利按年增近40%至78.13億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account